# US 2025/0059240 A1 · Antigenic Respiratory Syncytial Virus Polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0059240 A1
- Document ID: US20250059240A1
- Status: Published application
- Kind: A1
- Application number: 18/775,573
- Filed: 2024-07-17
- Published: 2025-02-20
- Earliest claimed: 2018-04-03
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Gary J. Nabel; Chih-Jen Wei; Kurt Swanson; Pradeep Dhal; Ram Dharanipragada; Magnus Besev
- Web page: https://patentgrep.com/patent/US20250059240A1

## CPC

- A61K 39/12: Viral antigens
- C07K 14/195: from bacteria
- A61P 31/14: for RNA viruses
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure relates to antigenic respiratory syncytial virus (RSV) polypeptides for use in eliciting antibodies against RSV. Also disclosed are antigenic polypeptides comprising an RSV polypeptide and a ferritin protein.

## Claims

### Claim at position 1

-39. (canceled)

### Claim 40

An antigenic respiratory syncytial virus (RSV) polypeptide comprising an RSV F polypeptide, wherein an asparagine of the RSV F polypeptide is glycosylated, thereby blocking an epitope of the RSV F polypeptide that is shared between pre-fusion RSV F and post-fusion RSV F, wherein the RSV F polypeptide comprises a sequence having at least 90% identity to amino acids 1-478 of SEQ ID NO: 17, and wherein the asparagine corresponds to position 288, 308, or 467 of SEQ ID NO: 17.

### Claim 41 (depends on 40)

The antigenic RSV polypeptide of claim 40, wherein the RSV F polypeptide is a pre-fusion RSV F.

### Claim 42 (depends on 40)

The antigenic RSV polypeptide of claim 40, wherein the RSV F polypeptide is recognized by a pre-fusion RSV F-specific antibody selected from D25 or AM14.

### Claim 43 (depends on 41)

The antigenic RSV polypeptide of claim 41, wherein the pre-fusion RSV F comprises an epitope not found on post-fusion RSV F.

### Claim 44 (depends on 40)

The antigenic RSV polypeptide of claim 40, wherein the RSV F polypeptide is a post-fusion RSV F.

### Claim 45 (depends on 40)

The antigenic RSV polypeptide of claim 40, wherein the asparagine corresponds to a non-asparagine residue in a wild-type RSV F sequence (SEQ ID NO: 26), wherein the non-asparagine residue corresponds to position 328, 348, or 507 of SEQ ID NO: 26.

### Claim 46 (depends on 40)

The antigenic RSV polypeptide of claim 40, further comprising a ferritin protein.

### Claim 47

An antigenic RSV polypeptide comprising an RSV F polypeptide and a ferritin protein, wherein the ferritin protein comprises a mutation replacing a surface exposed amino acid with a cysteine, and wherein the RSV F polypeptide comprises a sequence having at least 90% identity to amino acids 1-478 of SEQ ID NO: 17.

### Claim 48 (depends on 47)

The antigenic RSV polypeptide of claim 47, wherein the ferritin comprises one or more of E11C, S25C, S71C, A74C, K78C, S99C, and S110C mutations corresponding to the H. pylori ferritin sequence of SEQ ID NO: 209 as determined by pair-wise or structural alignment, or one or more corresponding mutations in a non-H. pylori ferritin as determined by pairwise or structural alignment.

### Claim 49 (depends on 46)

The antigenic RSV polypeptide of claim 46, comprising one or more immune-stimulatory moieties linked to the ferritin via a surface-exposed amino acid of the ferritin, wherein the surface-exposed amino acid is a cysteine resulting from a mutation.

### Claim 50 (depends on 46)

The antigenic RSV polypeptide of claim 46, wherein the ferritin comprises a mutation replacing a surface-exposed asparagine with a non-asparagine amino acid, wherein the asparagine is at a position corresponding to position 18 of H. pylori ferritin sequence of SEQ ID NO: 209 as determined by pair-wise or structural alignment, or is at an analogous position in a non-H. pylori ferritin as determined by pairwise or structural alignment.

### Claim 51 (depends on 46)

The antigenic RSV polypeptide of claim 46, wherein the ferritin comprises a mutation replacing an internal cysteine with a non-cysteine amino acid, wherein the internal cysteine is at position 30 of the H. pylori ferritin sequence of SEQ ID NO: 209, or is at a position that corresponds to position 30 of the H. pylori ferritin sequence of SEQ ID NO: 209 as determined by pair-wise or structural alignment.

### Claim 52 (depends on 46)

The antigenic RSV polypeptide of claim 46, wherein the RSV F polypeptide comprises an epitope not found on post-fusion RSV F which is a site 0 epitope, wherein the site 0 epitope comprises amino acid residues 62-69 and 196-209 of SEQ ID NO: 26.

### Claim 53 (depends on 40)

The antigenic RSV polypeptide of claim 40, wherein the RSV F polypeptide lacks a furin cleavage site, wherein a linker is present in place of the furin cleavage site.

### Claim 54 (depends on 46)

A ferritin particle comprising the antigenic RSV polypeptide of claim 46.

### Claim 55 (depends on 40)

A composition comprising the antigenic RSV polypeptide of claim 40 and an RSV G polypeptide.

### Claim 56 (depends on 40)

A method of eliciting an immune response to RSV or protecting a subject against RSV infection comprising administering the antigenic RSV polypeptide of claim 40 to a human subject.

### Claim 57 (depends on 40)

A nucleic acid encoding the antigenic RSV polypeptide of claim 40, wherein the nucleic acid is an mRNA or DNA.

### Claim 58

An antigenic respiratory syncytial virus (RSV) polypeptide comprising a sequence having at least 90% identity to amino acids 1-478 of SEQ ID NO: 17.
